Affinity enhancement of HER2-binding Z(HER2:342) affibody via rational design approach: a molecular dynamics study

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Biomolecular Structure and Dynamics

• Publication date

  2014-08-19

• Fields of study

  Medicine, Chemistry, Engineering

• Identifiers
  DOI 10.1080/07391102.2013.842499PMID 24125055
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The HER2-Binding Affibody Molecule (ZHER2∶342)2 Increases Radiosensitivity in SKBR-3 Cells

  2012cited by this paper
• New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

  2012cited by this paper
• Structural basis for high-affinity HER2 receptor binding by an engineered protein

  2010cited by this paper
• Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

  2010cited by this paper
• Engineered affinity proteins for tumour‐targeting applications

  2009cited by this paper
• Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line.

  2008influential reference
• Herceptin.

  2008cited by this paper
• HER‐2‐Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy

  2008cited by this paper
• Affibody Molecules for In vivo Characterization of HER2-Positive Tumors by Near-Infrared Imaging

  2008cited by this paper
• [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.

  2007cited by this paper
• Computational design of antibody-affinity improvement beyond in vivo maturation

  2007cited by this paper
• Computational design of a new hydrogen bond network and at least a 300-fold specificity switch at a protein-protein interface.

  2006cited by this paper
• Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

  2006influential reference
• Barnase thermal titration via molecular dynamics simulations: detection of early denaturation sites.

  2006cited by this paper
• Affinity enhancement of an in vivo matured therapeutic antibody using structure‐based computational design

  2006cited by this paper
• Recapitulation and design of protein binding peptide structures and sequences.

  2006cited by this paper
• Computational de novo design and characterization of a four-helix bundle protein that selectively binds a nonbiological cofactor.

  2005cited by this paper
• FastContact: rapid estimate of contact and binding free energies

  2005cited by this paper
• GROMACS: Fast, flexible, and free

  2005influential reference
• Monoclonal antibody therapy of cancer.

  2005cited by this paper
• STRIDE: a web server for secondary structure assignment from known atomic coordinates of proteins

  2004cited by this paper
• Epidermal growth factor receptor inhibition strategies in oncology.

  2004cited by this paper
• Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

  2003cited by this paper
• Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).

  2003cited by this paper
• Automated design of specificity in molecular recognition

  2003cited by this paper
• Computer-aided design of a PDZ domain to recognize new target sequences

  2002cited by this paper
• The PyMOL Molecular Graphics System

  2002cited by this paper
• Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.

  2002cited by this paper
• Biology of HER2 and Its Importance in Breast Cancer

  2001cited by this paper
• Untangling the ErbB signalling network

  2001influential reference
• The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

  2001cited by this paper
• The EGF receptor: a nexus for trafficking and signaling

  2000cited by this paper
• EGF receptor.

  1999cited by this paper
• Determination of atomic desolvation energies from the structures of crystallized proteins.

  1997cited by this paper
• Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain

  1997cited by this paper
• De novo protein design: fully automated sequence selection.

  1997cited by this paper
• SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling

  1997cited by this paper
• VMD: visual molecular dynamics.

  1996cited by this paper
• De novo design of the hydrophobic cores of proteins

  1995cited by this paper
• Complex salt bridges in proteins: statistical analysis of structure and function.

  1995cited by this paper
• The stability and unfolding of an IgG binding protein based upon the B domain of protein A from Staphylococcus aureus probed by tryptophan substitution and fluorescence spectroscopy.

  1994cited by this paper
• Humanization of an anti-p185HER2 antibody for human cancer therapy.

  1992cited by this paper
• Monoclonal antibody therapy of cancer.

  1990cited by this paper
• Strength and co-operativity of contributions of surface salt bridges to protein stability.

  1990cited by this paper
• A rapid method of calculating charge-charge interaction energies in proteins.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987influential reference
• A synthetic IgG-binding domain based on staphylococcal protein A.

  1987cited by this paper
• The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

  1984cited by this paper

• A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells

  2024cites this paper
• Affibody molecules for molecular imaging and targeted drug delivery in the management of breast cancer.

  2018cites this paper
• Rational affinity enhancement of fragmented antibody by ligand-based affinity improvement approach.

  2018cites this paper
• Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches

  2017cites this paper